On April 12, 2021 Aptus Clinical, as the full service CRO provider for the Phase 1b/2a Cancer Appetite Recovery Study (CAReS), reported that it has assisted Artelo Biosciences in the planning and running of this important study which investigates the potential for ART27.13 (a peripherally synthetic cannabinoid agonist), to alleviate anorexia associated with cancer, a condition with significant unmet need and no licensed treatments (Press release, Aptus Clinical, APR 12, 2021, View Source [SID1234577899]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Steve McConchie, CEO at Aptus Clinical said ‘The CAReS study is an important investigation in cancer anorexia, and we are delighted that the partnership we have developed with Artelo has achieved the important milestone of first patient recruited and dosed. We are excited to be working with Artelo in assessing whether ART27.13 can make a difference to patients who are suffering from this distressing condition and improve their quality of life.

Gregory D. Gorgas, President and CEO of Artelo Biosciences commented "Artelo are excited to be starting the CAReS trial investigating ART27.13 in patients who currently have no licensed options to alleviate the devastating condition of cancer-associated anorexia. ART27.13 has already demonstrated significant weight gain potential in patients with chronic back pain who were otherwise healthy, and we look forward to seeing the results when translated into anorexic cancer patients who have suffered significant weight loss."